New Trial Using Transcranial Electromagnetic Treatment for Alzheimer's Disease Begins
New medical technology is being used in a just-started clinical trial in patients with Alzheimer's disease (AD). The trial involves treatment with a wearable head device that provides transcranial electromagnetic treatment (TEMT) to the brain.
Several mechanisms not provided by any drug currently in AD clinical trials seem to be providing these cognitive benefits. First, TEMT breaks down the small protein aggregates (amyloid oligomers) inside brain cells that are now thought to initiate AD development in the brain. TEMT then dramatically increases the very low energy production of AD brain cells by enhancing their mitochondrial function.
The clinical trial is unique in that patients with AD will receive treatments in-home, as administered by their family caregivers. The NeuroEM 1000 head device, worn twice daily for 1-hour treatments, allows complete mobility of the patient for in-home activities.
Source.“Alzheimer's Clinical Trial Begins with Pioneering Medical Device.” (2016, December 6). Retrieved January 5, 2017, from http://prn.to/2hV9sln.
U.S. Food and Drug Administration Approves Synjardy® XR to Treat Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used with diet and exercise, Synjardy XR is indicated to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be taken.
FDA approval of Synjardy XR is based on results from multiple clinical trials examining the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea. Synjardy XR is not for the treatment of type 1 diabetes or diabetic ketoacidosis.
Source.“U.S. FDA Approves Synjardy® XR (Empagliflozin/Metformin Hydrochloride Extended-Release) Tablets for Adults With Type 2 Diabetes.” (2016, December 12). Retrieved January 5, 2017, from http://prn.to/2gHPFbv.